Adrenergic stimulation and blocking of hormonal secretion activity of cultured cow granulosa cells.
The aim of this study was to determine the influence of alpha- and beta-stimulators (alpha-stimulator: detomidinum HCl) as well as blockers (alpha1-blocker: doxazosin, alpha2-blocker: yohimbinum HCL, beta-blocker: carazolol) on bovine granulosa cells culture from preovulatory follicles. The cell culture was passed in TCM 199 medium with 10% FCS and antibiotics. Tested substances were added to the culture medium in different concentrations. The experiment began when at least 80% of the wells were covered (in four well culture dish of NUNCK-DK). The culture medium was collected every 24 h for hormone analysis. Hormone levels of T, E2, and P4 were determined. The culture was used up to 120 hours. Our results showed a decrease in P-4 secretion after detomidinum addition for all tested concentrations. A slight testosterone level increase was seen in the first 24 hours and then its concentration remained at a constant low level. A slight increase in 17-beta estradiol secretion was also observed. After yohimbinum addition, a statistically significant decrease of progesterone was observed for all concentrations tested. No significant changes were observed at other hormones levels when compared with the control. Doxazosin, when added into the culture medium, did not cause any statistically significant changes in hormone secretions. The addition of carazolol caused a significant decrease in progesterone secretion after culturing for 48 hours. Changes observed in other hormones levels did not differ statistically from the control. These results seem to support the hypothesis that drugs stimulating and blocking adrenergic receptors may play some role in ovarian steroidogenesis in cows.
Gajewski
Z
Z
Department of Animal Reproduction, Faculty of Veterinary Medicine, Warsaw Agricultural University, Warsaw, Poland. zgajewski@supermedia.pl
Faundez
R
R
Thun
R
R
Pawliński
B
B
D058646:Adrenergic alpha-1 Receptor Agonists; D058668:Adrenergic alpha-1 Receptor Antagonists; D058647:Adrenergic alpha-2 Receptor Agonists; D058669:Adrenergic alpha-2 Receptor Antagonists; D000316:Adrenergic alpha-Agonists / Q000494:pharmacology*; D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000818:Animals; D002417:Cattle; D002478:Cells, Cultured; D017292:Doxazosin / Q000494:pharmacology; D004958:Estradiol / Q000378:metabolism; D005260:Female; D005498:Follicular Phase; D006107:Granulosa Cells / Q000187:drug effects* / Q000378:metabolism*; D007093:Imidazoles / Q000494:pharmacology*; D006080:Ovarian Follicle / Q000166:cytology; D011374:Progesterone / Q000378:metabolism; D011412:Propanolamines / Q000494:pharmacology; D012636:Secretory Rate / Q000187:drug effects; D013739:Testosterone / Q000378:metabolism; D015016:Yohimbine / Q000494:pharmacology
D058646:Adrenergic alpha-1 Receptor Agonists; D058668:Adrenergic alpha-1 Receptor Antagonists; D058647:Adrenergic alpha-2 Receptor Agonists; D058669:Adrenergic alpha-2 Receptor Antagonists; D000316:Adrenergic alpha-Agonists; D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D007093:Imidazoles; D011412:Propanolamines; C014382:carazolol; D015016:Yohimbine; D013739:Testosterone; D011374:Progesterone; D004958:Estradiol; C041255:detomidine; D017292:Doxazosin